You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

RAXAR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Raxar, and when can generic versions of Raxar launch?

Raxar is a drug marketed by Otsuka and is included in one NDA.

The generic ingredient in RAXAR is grepafloxacin hydrochloride. Additional details are available on the grepafloxacin hydrochloride profile page.

US Patents and Regulatory Information for RAXAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otsuka RAXAR grepafloxacin hydrochloride TABLET;ORAL 020695-001 Nov 6, 1997 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Otsuka RAXAR grepafloxacin hydrochloride TABLET;ORAL 020695-002 May 14, 1998 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Otsuka RAXAR grepafloxacin hydrochloride TABLET;ORAL 020695-003 May 14, 1998 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for RAXAR

See the table below for patents covering RAXAR around the world.

Country Patent Number Title Estimated Expiration
Japan 2654537 ⤷  Try a Trial
Spain 2091180 ⤷  Try a Trial
Spain 2172734 ⤷  Try a Trial
European Patent Office 0565132 Composés benzohétérocycliques (Benzoheterocyclic compounds) ⤷  Try a Trial
European Patent Office 0823413 Intermédiaires pour la préparation de composés benzohhétérocycliques (Intermediates for the preparation of benzoheterocyclic compounds) ⤷  Try a Trial
Japan H0696557 ⤷  Try a Trial
Netherlands 980011 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for RAXAR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0287951 C980011 Netherlands ⤷  Try a Trial PRODUCT NAME: GREPAFLOXACINUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AA NVAARDBAAR ZOUT OF IN DE VORM VAN EEN ESTER MET EEN ALKANOL MET 1-6 KOOLSTOFATOMEN, IN HET BIJZONDER GREPAFLOXACINI HYDROCHLOR IDUM SESQUIHYDRATUM; NAT. REGISTRATION NO/DATE: RVG 21894, RVG 21895 19971113; FIRST REGISTRATION: DE 40682.00.00, 40682.01.00, 40682.02.00 19970731
0287951 SPC/GB98/016 United Kingdom ⤷  Try a Trial PRODUCT NAME: GREPAFLOXACIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT INCLUDING GREPAFLOXACIN HYDROCHLORIDE SESQUIHYDRATE; REGISTERED: DE 40682.00.00 19970731; DE 40682.01.00 19970731; DE 40682.02.00 19970731; UK 10949/0299 19971209; UK 10949/0300 19971209
0451216 99C0028 Belgium ⤷  Try a Trial PRODUCT NAME: GREPAFLOXACINE; CHLORHYDRATE SESQUIHYDRATE; NAT. REGISTRATION NO/DATE: NL 23 373 19990525; FIRST REGISTRATION: DE - 4062.00.00 19970731
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.